Clinical Trial

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.
Trial Details
NCT Number NCT06931613
Lead Sponsor St. Petersburg State Pavlov Medical University
Conditions Relapsed or Refractory Hodgkin Lymphoma, Children, Nivolumab, Autologous Haemopoietic Stem Cell Transplant
Enrollment 20 participants
Start Date 2022-06-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-17